Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03029429 · ClinicalTrials.gov registry record · Phase 2
Theophylline Treatment for Pseudohypoparathyroidism
A Phase 2 study of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT03029429: Active Phase 2 study of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism, sponsored by Vanderbilt University Medical Center.
NCT03029429 is a Phase 2 study of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03029429, a Phase 2 study of Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
Pseudohypoparathyroidism is a genetic disorder with limited treatment options. Patients have early-onset obesity, short stature and increased risk of type 2 diabetes. This phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. The investigators hypothesize that theophylline will cause weight loss, improve glucose tolerance and slow growth plate closure in children and young adults.
Primary Outcome
BMI will be expressed a percent of the 95th percentile
Conditions Studied
Interventions
- DRUG Theophylline
- DRUG Placebos
Study Locations (1)
Tennessee
- Ashley Shoemaker - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2018-09-01 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 2 |
What the registry record for NCT03029429 still lists
NCT03029429 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Albright Hereditary Osteodystrophy appearing as the primary indexed condition, and to 2 interventions - of which Theophylline is the first listed.
NCT03029429 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT03029429 about?
NCT03029429 is a clinical study titled "Theophylline Treatment for Pseudohypoparathyroidism". Pseudohypoparathyroidism is a genetic disorder with limited treatment options. Patients have early-onset obesity, short stature and increased risk of type 2 diabetes. This phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. The i...
What is the current status of trial NCT03029429?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2018-09-01. Estimated completion is 2026-12-01.
What conditions does trial NCT03029429 study?
This clinical trial studies the following conditions: Albright Hereditary Osteodystrophy, Pseudohypoparathyroidism.
What interventions are being tested in trial NCT03029429?
The interventions under investigation include: Theophylline (DRUG), Placebos (DRUG).
Who is sponsoring clinical trial NCT03029429?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03029429 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Albright Hereditary Osteodystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03029429's enrollment target sits among peer trials
29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI